Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Sudha Vippagunta is active.

Publication


Featured researches published by Sudha Vippagunta.


International Journal of Pharmaceutics | 2011

Comparison of HPMC based polymers performance as carriers for manufacture of solid dispersions using the melt extruder.

Indrajit Ghosh; Jennifer Snyder; Radha Vippagunta; Marilyn Alvine; Ronak Vakil; Wei-Qin Tong; Sudha Vippagunta

Preparation of amorphous solid dispersions using hot-melt extrusion process for poorly water soluble compounds which degrade on melting remains a challenge due to exposure to high temperatures. The aim of this study was to develop a physically and chemically stable amorphous solid dispersion of a poorly water-soluble compound, NVS981, which is highly thermal sensitive and degrades upon melting at 165 °C. Hydroxypropyl Methyl Cellulose (HPMC) based polymers; HPMC 3cps, HPMC phthalate (HPMCP) and HPMC acetyl succinate (HPMCAS) were selected as carriers to prepare solid dispersions using hot melt extrusion because of their relatively low glass transition temperatures. The solid dispersions were compared for their ease of manufacturing, physical stability such as recrystallization potential, phase separation, molecular mobility and enhancement of drug dissolution. Two different drug loads of 20 and 50% (w/w) were studied in each polymer system. It was interesting to note that solid dispersions with 50% (w/w) drug load were easier to process in the melt extruder compared to 20% (w/w) drug load in all three carriers, which was attributed to the plasticizing behavior of the drug substance. Upon storage at accelerated stability conditions, no phase separation was observed in HPMC 3cps and HPMCAS solid dispersions at the lower and higher drug load, whereas for HPMCP, phase separation was observed at higher drug load after 3 months. The pharmaceutical performance of these solid dispersions was evaluated by studying drug dissolution in pH 6.8 phosphate buffer. Drug release from solid dispersion prepared from polymers used for enteric coating, i.e. HPMCP and HPMCAS was faster compared with the water soluble polymer HPMC 3cps. In conclusion, of the 3 polymers studied for preparing solid dispersions of thermally sensitive compound using hot melt extrusion, HPMCAS was found to be the most promising as it was easily processible and provided stable solid dispersions with enhanced dissolution.


Pharmaceutical Development and Technology | 2012

Key considerations for optimization of formulation and melt-extrusion process parameters for developing thermosensitive compound

Indrajit Ghosh; Radha Vippagunta; Shoufeng Li; Sudha Vippagunta

The melt-extrusion process is currently applied in the pharmaceutical field in the manufacturing of a variety of dosage forms and formulations, including solid dispersions. Though this technology is considered efficient and continuous, there are potential challenges of which, additional thermal degradation of drug substance because heat stress and shear forces are of a primary concern. This paper attempts to understand the impact of thermal and/or mechanical components of the melt-extrusion process on the stability of a thermosensitive drug substance during scale-up. The overall degradation profile of the drug substance was correlated with the various physical changes made to the extruder as well as the process temperature. The results suggested that the degradation profile of a thermosensitive drug substance could be controlled by proper design of screw assemblies and by optimization of screw rotations per minute, process temperature, and feed rate during development and scale-up.


Journal of Pharmaceutical Sciences | 2007

Factors affecting the formation of eutectic solid dispersions and their dissolution behavior

Sudha Vippagunta; Zeren Wang; Stefanie Hornung; Steven L. Krill


Archive | 2007

Method of making solid dispersions of highly crystalline therapeutic compounds

Indrajit Ghogh; Jennifer Snyder; Wei Quin Tong; Sudha Vippagunta


Archive | 2009

Galenical Formulation Comprising Aliskiren and Process for its Preparation by Melt Extrusion Granulation

Indrajit Ghosh; James Kowalski; Jennifer Snyder; Wei-Qin Tong; Sudha Vippagunta


Archive | 2011

Dual-layer or monolayer form fixed dose combination of aliskiren and amlodipine

Stephen Valazza; Frank Wagner Robert; Sudha Vippagunta


Archive | 2010

Galenical Formulations of a Fixed Dose Combination of Valsartan and Aliskiren

Indrajit Ghosh; Shoufeng Li; Wei-Qin Tong; Sudha Vippagunta; Hong Wen


Archive | 2017

Tablet Formulation Of 2-Fluoro-N-Methyl-4-[ 7- ( Quinolin-6-Ylmethyl) Imidazo [1,2-B] [1,2,4] Triazin-2-YL] Benzamide

Elisabete Goncalves; Christin Tauchmann; Shau-Fong Yen; Sudha Vippagunta; Zhixin Zong


Archive | 2015

Formulation de comprimé de 2-fluoro-n-méthyl-4-[7-(quinoline -6-ylméthyl) imidazo[1,2-b] [1,2,4]triazine -2-yl]benzamide

Elisabete Goncalves; Christin Tauchmann; Shau-Fong Yen; Sudha Vippagunta; Zhixin Zong


Archive | 2010

Formulations galéniques d'une combinaison de dose fixe de valsartan et d'aliskiren

Indrajit Ghosh; Shoufeng Li; Wei-Qin Tong; Sudha Vippagunta; Hong Wen

Collaboration


Dive into the Sudha Vippagunta's collaboration.

Researchain Logo
Decentralizing Knowledge